Gastritis is a common condition that causes inflammation and damage to the lining of the stomach. Gastritis Treatment involves the use of various drugs such as proton pump inhibitors, antibiotics, H2 blockers, and others to provide relief from symptoms and heal the stomach lining. The global gastritis treatment market is estimated to be valued at US$ 131.76 Billion in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030.
Gastritis occurs due to various causes like excessive consumption of alcohol, infection with bacteria like Helicobacter pylori, long-term usage of painkillers, and stress. Gastritis treatment aims to eliminate the causal agent and allow the stomach lining to heal. Proton pump inhibitors are commonly prescribed as they reduce acid production, providing relief from symptoms and promoting healing. The rising prevalence of risk factors such as smoking, alcohol consumption, and unhealthy lifestyles has contributed to the increasing incidence of gastritis globally.
Key Takeaways
Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited.
The market provides opportunities for growth owing to the rising incidence of dyspepsia and gastric ulcers caused by H. pylori infections.
The increasing research and development activities for novel drug formulations are expected to drive the global expansion of the gastritis treatment market during the forecast period.
Market Drivers
The key driver propelling the gastritis treatment market growth is the rising prevalence of risk factors associated with gastritis. Conditions like obesity, smoking, excessive alcohol consumption weaken the stomach lining, making it more prone to inflammation. According to the National Institute of Diabetes and Digestive and Kidney Diseases, in the United States, around 25% of the population is estimated to suffer from gastritis attributed to these risk factors at some point. The increasing cases attributable to modifiable risk factors are expected to drive the demand for treatment options in the coming years.
PEST Analysis
Political: Changes in government regulations and healthcare reforms across various countries have impacted the treatment patterns for gastritis. New guidelines introduced for diagnosis and management of gastritis has also been influential.
Economic: Volatility in the economic conditions and fluctuations in disposable income levels of patients impacts the demand for gastritis treatment drugs and procedures. Affordability of treatment is a major factor considered for medication adherence.
Social: Changing lifestyles and eating habits have increased the prevalence of gastritis over years. Adoption of spicy and junk food along with increased consumption of alcohol and smoking contributes to gastritis.
Technological: Advancements in endoscopy devices and procedures allow for improved gastritis diagnosis. Development of novel drug delivery systems and targeted drug formulations help achieve better clinical outcomes for gastritis patients.
The North America region accounts for the largest market share in terms of value owing to developed healthcare infrastructure and high treatment seeking rate for gastritis. Easy accessibility to advanced diagnostic procedures and high adoption of prescribed medications drive the North America gastritis treatment market.
The Asia Pacific region is poised to exhibit the fastest growth over the forecast period. Rising prevalence of gastritis due to changing lifestyle preferences and increasing awareness about available treatment options contribute to market growth in Asia Pacific.
